| Biomarker ID | 1881 |
| PMID | 30446464 |
| Year | 2018 |
| Biomarker | Testosterone |
| Biomarker Basis | Concentration Based (ng/mL) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Decreased in Biochemical Recurrence Free Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 3.32 |
| Effect on Pathways | NA |
| Experiment | Overall Survival Vs No Overall Survival |
| Type of Biomarker | Prognostic |
| Cohort | 106 Japanese patients were selected for the study. 12 patients were treated with Cabazitaxel and selected for this analysis. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.043 |
| Method Used | electrochemiluminescence immunoassay |
| Clinical | No |
| Remarks | Progression was defined according to consecutive PSA increments resulting in 25% increases and 2 ng/ml over the nadir despite consecutive ADT, or progression of soft-tissue lesions or appearance of 2 lesions on a bone scan . Only patients treated with Cabazitaxel were selected for this |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |